Evaluation of Hot Deformation and Dynamic Recrystallization Behaviors of Advanced Reduced-Activated Alloy (ARAA)

Sang‑Wook Kim,Hyeon‑Woo Son,Taek‑Kyun Jung,Young‑Bum Chun,Yi‑Hyun Park,Ji‑Woon Lee,Soong‑Keun Hyun 대한금속·재료학회 2019 METALS AND MATERIALS International Vol.25 No.4

The hot deformation behavior of advanced reduced-activation alloy (ARAA) was investigated using hot torsion tests. Thefl ow stress decreased as deformation temperature increased and as strain rate decreased. The fl ow behavior demonstratedthe typical dynamic recrystallization (DRX). Based on the constitutive analysis of peak stress, the activation energy for hotdeformation was found to be 330.3 kJ mol −1 . Peak stress was analyzed as a function of the Zener–Hollomon parameter, andcalculated and experimental values were in good agreement. A DRX kinetic model for ARAA was derived with deformationconditions based on the Avrami-type model. It was confi rmed that the volume fraction of dynamically recrystallized grainsincreased as deformation temperature increased and as strain rate decreased. The necklace structure and grain boundarybulging were observed in the deformed microstructure of ARAA. The suggested DRX mechanism for ARAA during hotworking is discontinuous DRX.

요추 수술 예정 환자에서 실시한 선택적 신경근 차단술의 5년 추시 결과

심대무(Dae Moo Shim),김태균(Tae Kyun Kim),오성균(Sung Kyun Oh),최윤홍(Yun Hong Choi),이석중(Suk Jung Lee) 대한정형외과학회 2009 대한정형외과학회지 Vol.44 No.1

목적: 하지 방사통을 호소하는 환자의 수술 준비 과정에서 선택적 척추 신경근 차단술을 실시하고, 그 효과가 얼마나 오래 유지되는지를 알아 보고자 5년 이상 추시된 환자를 대상으로 분석하여 그 결과를 보고 하고자 한다. 대상 및 방법: 2000년 1월에서 2000년 12월까지 하지 방사통으로 타 병원 혹은 본원에서 수술적 치료를 권유받은 환자 중 수술 준비 과정에서 진단 및 치료 목적으로 선택적 척추 신경근 차단술을 시행한 환자를 대상으로 하였으며, 이중 5년 이상 추시가 가능하였던 69예를 대상으로 하였다. 결과분석은 진료기록부와 전화 인터뷰를 통해 하였으며. 신경차단술 시행군과 수술을 시행한 군의 치료결과 분석은 Kim's criteria (김의 평가기준), VAS(Visual analog scale) score를 이용하였다. 결과: 연구 대상 환자 69예 중 37예에서는 차단술 후에 증상 호전이 없어 수술을 시행하였고, 32예에서는 신경차단술 만으로 증상호전 되었다. 젊은 사람(60세 미만)에서 보존적 요법보다는 수술을 하는 경향이 많았으며, 이환 기간이 길수록(6개월 이상) 신경근 차단술 보다는 수술하는 경우가 높았다. 차단술 만으로도 호전된 32예의 환자 추시 결과상 다른 치료 없이 증상 호전이 지속되었던 환자는 17예(24.6%)였고 증상이 재발하여 추가 치료를 필요로 한 환자는 15예이었다. 이중 4예는 수술적 치료를 시행하였다. 결론: 수술이 예정된 하지 방사통 환자를 대상으로 수술 준비 기간 동안에 신경근 차단술을 시행하여 그 중 일부에서는 장기 추시에서도 증상 호전이 지속 되었다. 따라서 신경차단술은 수술 전에 한번 시도해 볼 만한 방법 중의 하나로 사료된다. Purpose: To evaluate the effectiveness of a selective nerve root block (SNRB) in patients with sciatica before surgery through a more than 5 year follow up. Materials and Methods: Between January 2000 and December 2000, patients with sciatica, who were recommended to undergo surgery to diagnose and treat sciatica by other clinics or at our hospital, were selected to undergo SNRB before surgery. Among them, 69 patients were followed up for 5 years. The analysis was based on the patients' medical records and telephone interviews, and the treatment results in the SNRB group and operation group were analyzed using Kim's criteria and the Visual Analog Scale score. Results: Among the 69 patients, there was no improvement in symptoms in 37 patients after SNRB. Therefore, they underwent surgery. The symptoms of the remaining 32 patients were improved by SNRB. Overall, younger patients and those with a longer symptom duration required surgery. Conclusion: SNRB was performed on patients with sciatica who were scheduled to undergo surgery. Some patients showed improvement in their symptoms in the long term. Therefore, SNRB should be considered as a treatment option prior to surgery.

Case report : SIADH Associated with Prostate Cancer

( Kyun Sang Lee ),( Taek Won Kang ),( Seong Kwon Ma ),( Soo Wan Kim ),( Nam Ho Kim ),( Ki Chul Choi ) 대한전해질,혈압학회 2007 Electrolytes & Blood Pressure Vol.5 No.1

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most common disease leading to hyponatremia, and it is characterized by an inappropriately elevated serum ADH level relative to serum osmolality. This syndrome may occur in a variety of clinical settings including malignancies. However, it is rarely observed in association with prostate cancer. Moreover, its pathogenesis and clinical characteristics have not been completely understood. We report a case of SIADH associated with prostate cancer in a 64-year-old male patient with a literature review.

Inhibition of L-Type Amino Acid Transporter Modulates the Expression of Cell Cycle Regulatory Factors in KB Oral Cancer Cells

Kim, Chun Sung,Moon, In-Sung,Park, Ju-Hyun,Shin, Woo-Cheol,Chun, Hong Sung,Lee, Sook-Young,Kook, Joong-Ki,Kim, Heung-Joong,Park, Joo-Cheol,Endou, Hitoshi,Kanai, Yoshikatsu,Lee, Byung-Kwon,Kim, Do Kyun Pharmaceutical Society of Japan 2010 BIOLOGICAL & PHARMACEUTICAL BULLETIN Vol.33 No.7

<P>The purpose of this study was to examine the effect of 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH), an inhibitor of L-type amino acid transporters, on the cell growth suppression in KB human oral cancer cells and to study the roles of cell cycle regulatory factors in the BCH-induced growth inhibition. The effect of BCH on cell growth suppression and the influence of BCH to cell cycle regulatory factors in KB cell growth inhibition were examined using cell cycle analysis, immunoblotting and immunoprecipitation. The BCH treatment induced cell cycle arrest at G1 phase in KB cells. The expression of cyclin D3 was remarkably decreased by BCH treatment. The BCH inhibited the expression of cyclin-dependent protein kinase 6 (CDK6) in a time-dependent manner. In addition, the expression of CDK inhibitor p27 was increased by BCH treatment in KB cells, but not CDK inhibitors p21 and p15. These results suggest that, in KB cells, the inhibition of LAT1 by BCH causes cell cycle arrest at G1 phase by inhibiting cyclin D3–CDK6 complex whereas increasing expression of a CDK inhibitor p27.</P>

Advanced Aggressive Non Hodgkin's Lymphima Treated with CHOP(Cyclophosphamide, Doxorubicin, Vincrstine and Prednisone) or CHOP plus Bleomycin with or without Focal Irradiation

Kim, Chul Soo,Kwon, Sung Woon,Kim, Yong Kyun,Sung, Young Joo,Lim, Chang Young,Kim, Yong Bok,Kim, Joon Hee,Suh, Hyun Suk,Kim, Sung Rok,Lee, Young Soo,Kim, Re Hwe 인제대학교 1993 仁濟醫學 Vol.14 No.4

예후불량 조직형 비호치킨 림프종으로 진단받은 1명의 제 3병기 환자 및 17명의 제 4병기 환자에게 Oncovin 1.5mg을 제 1일에, Adriamycin 50mg을 제 2일에, Cytoxan 400mg을 제 3, 4, 5일에 정맥주사하고, Prednisone 60mg을 제 1일에서 5일까지 경구 투여하는 동시에 경우에 따라 Bleomycin 15mg을 제 6,7일에 정맥주사하거나 대형의 종괴, 화학요법에 저항을 보이는 종괴, 골절의 위험이 있는 골침윤 부위 및 중추신경계의 종양침윤에 대하여 국소적인 방사선 요법을 시행하였다. 조직학적으로 11명은 미만성 대세포, 3명은 미만성 분절 소세포, 2명은 림프아구, 1명은 면역아구, 1명은 여포성 대세포형 림프종을 가지고 있었으며, 남녀의 비율은 16대 2, 연령은 15세에서 74세(중앙치 44)였으며 7명은 B증상을 가지고 있었다. 항암화학요법은 2차례에서 14차례까지 시행가능하였으며(중앙치 4) 5명에서는 Bleomycin을 추가하였고 8명에서는 국소적 방사선 조사를 시행하였다. 판정이 가능하였던 17명중 6명(35%)은 완전관해, 6명(35%)은 부분관해, 5명(30%)은 무반응을 보였고 완전관해의 지속기간은 6개월에서 27개월(중앙치 12.5)이었으며 완전관해군의 생존기간은 14개월에서 64개월(중앙치 29), 부분관해군의 생존기간 중앙치는 7개월, 무반응군의 생존기간 중앙치는 6개월로서 전체환자의 생존기간 중앙치는 10개월이였고 전체환자의 5년 생존율은 6%였다. 치료로 인한 독성은 경미하였고 치료로 인한 사망례는 없었다. 완전관해율및 생존율의 부진함은 의학적 권고를 제대로 따르지 못한 상당수 환자의 불충분한 치료및 대다수 환자의 불량한 예후인자에서 기인하였다. 항암화학요법에 민감한 환자군에서는 충분한 횟수의 항암화학요법이 요구되며 항암화학요법에 저항을 보이거나 재발한 환자에서는 고식적인 항암화학요법보다 더욱 혁신적인 치료가 필요할것으로 사료된다. Eighteen patients histologically proven as disseminated aggressive non Hodgkin's lymphoma were treated wish CHOP(vincristine 1.5mg IV on day 1, doxorubicin 50mg IV on day 2, cyclophosphamide 400mg IV on days 3∼5, prednisone 60mg PO on days 1∼5) or CHOP plus bleomycin(15mg IV on days 6∼7) with or without focal irradiation. There were 16 male and 2 female patients with their ages ranging 15∼74( median 44). The histological subtypes consisted of diffuse large cell in 11, diffuse small cleaved cell in 3, lymphoblastic in 2, immunoblastic in 1, and follicular large cell in 1. One patient was in stage IIIA, 10 in stave IVA, and 7 in stage IVB. The number of courses of chemotherapy ranged 2∼14(median 4). Focal irradiation was given to 8 patients. Therapy related morbidity was minimal with no case of mortality. Among 17 evaluable patients, six(35%) attained CR(complete remission) with a median remission duration of 12.5 months(range 6∼27). Six(35%) responded partially and five(30%) did not respond. The median survival durations were 29 months(range 14∼64) in patients who entered CR, 7 months in who achieved PR(partial remission), and 6 months in non responders. The overall median survival duration was 10 months and 5 year survival rate 6% (1 in 17). The poor CR and long term survival rate seemed to be resulted from poor compliance of the patients on one hand rather than the defect of our regimen and from poor prognostic factors of our patient group on the other hand. A strict application of the treatment schedule is needed for the chemosensitive group and an innovative treatment is required for the relapsed or chemoresistant group.

Exploratory Factor Analysis of SME Internationalization: Factor Differences between AEO and Non-AEO Authorized Companies

Sung-Kyun Son,Tae-Joong Kim,So-Hyung Kim 한국유통과학회 2014 유통과학연구 Vol.12 No.7

Purpose - This study identified internationalization factors for-Korean SMEs and explored factor differences between AEO and non-AEO authorized companies. Research design, data, and methodology - The study was designed to assess internationalization factors for AEO authorization in Korea through a questionnaire survey and an empirical analysis. The questionnaires were conducted for AEO and Non-AEO authorized companies that were undergoing AEO authorization. The study was conducted through e-mail and AEO manager education classes. Ninety-five questionnaires were collected. We employed the exploratory factor analysis methodology to derive internationalization factors for KoreanSMEs, and explored the factor differences between AEO and Non-AEO authorized companies. Results - AEO authorized companies outperformed Non-AEO authorized companies in R&D and technology. This indicated that AEO authorized companies were recognized as reliable and safe companies by the Korea Customs Service and other Customs services in trade facilitation and customs clearance processes. Conclusions - This study has some implications for AEO authorization and internationalization processes, and involved the empirical analysis of SMEs and the exploratory factor analysis in the internationalization process.

Influences of Thiopurine Methyltransferase Genotype and Activity on Thiopurine-induced Leukopenia in Korean Patients With Inflammatory Bowel Disease: A Retrospective Cohort Study

Kim, Jae Hak,Cheon, Jae Hee,Hong, Seong Soo,Eun, Chang Soo,Byeon, Jeong-Sik,Hong, Sung Yi,Kim, Bo-Young,Kwon, Soon-ho,Kim, Seung Won,Han, Dong Soo,Yang, Suk-Kyun,Kim, Won Ho Lippincott WilliamsWilkins, Inc. 2010 Journal of clinical gastroenterology Vol.44 No.10

BACKGROUND AND AIM: Myelotoxicity has been shown to be very common in Korean patients with inflammatory bowel disease (IBD) during azathioprine (AZA) or 6-mercaptopurine (6–MP) treatment. The purpose of this study was to investigate the relative risk of the thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) genotypes and TPMT activity for the development of leukopenia in Korean IBD patients during AZA/6-MP treatment. METHODS: We retrospectively analyzed 286 Korean patients with IBD who had been treated with AZA/6-MP for at least 6 months between June 1996 and September 2006. Common TPMT mutations, including TPMT*1, *2, *3A, *3B, and *3C, and ITPA mutations, including 94C>A and IVS2+21A>C, were determined using a high-performance liquid chromatography method. TPMT activity was measured using liquid chromatography with coupled mass spectrometry/mass spectrometry. RESULTS: Leukopenia occurred in 118 cases (41.3%). TPMT *1/*3C was detected in 7 cases (2.4%), and ITPA 94 C>A was detected in 66 cases (23.1%), including 63 heterozygotes (22.1%) and 3 homozygotes (1.0%). The median TPMT activity was 9.3 U/mL (interquartile range 10.4, range 2.1 to 76.2). Cox regression analysis revealed that patients with heterozygous *3C type TPMT had a higher probability of leukopenia than those with wild type TPMT (P=0.02). Patients with intermediate TPMT activity had a lower probability of leukopenia than those with low activity (P=0.01). However, the ITPA genotype did not affect the risk of leukopenia. CONCLUSIONS: Our data showed that it could be helpful to examine TPMT genotypes and to measure TPMT activity in Korean patients taking AZA/6-MP to predict the development of leukopenia.

The Effect of Barbiturate Coma Therapy for the Patients with Severe Intracranial Hypertension : A 10-Year Experience

Kim, Young-Il,Park, Seung-Won,Nam, Taek-Kyun,Park, Yong-Sook,Min, Byung-Kook,Hwang, Sung-Nam The Korean Neurosurgical Society 2008 Journal of Korean neurosurgical society Vol.44 No.3

Objective : Barbiturate coma therapy (BCT) has been known to be an useful method to control increased intracranial pressure (IICP) refractory to medical and surgical treatments. We have used BCT for patients with severe IICP during the past 10 years, and analyzed our results with review of literatures. Methods : We analyzed 92 semicomatose or comatose patients with Glasgow coma scale (GCS) of 7 or less with severe IICP due to cerebral edema secondary to parenchymal damages irrespective of their causes. Forty patients who had received BCT with ICP monitoring from January 1997 to December 2006 were included in BCT group, and fifty-two patients who had been managed without BCT from January 1991 to December 1995 were divided into control group. We compared outcomes with Glasgow outcome scale (GOS) and survival rate between the two groups. Results : Good outcome (GOS=4 and 5) rates at 3-month after insult were 27.5% and 5.8% in BCT and control group, respectively (p<0.01). One-year survival rates were 35.9% and 12.5% in BCT and control group, respectively (p<0.01). In BCT group, the mean age of good outcome patients ($37.1{\pm}14.9$) was significantly lower than that of poor outcome patients ($48.1{\pm}13.5$) (p<0.05). Conclusion : With our 10-year experience, we suggest that BCT is an effective treatment method for severe IICP patients for better survival and GOS, especially for younger patients.

Intracellular Trafficking of Secretory Proteins in Plant Cells

Kim, Weon-Yeon,Lee, Kyun-Oh,Son, Hyo-Sppl,Lee, Sang-Yeol Gyeongsang National University, Chinju, Korea 1996 Plant molecular biology and biotechnology research Vol.1996 No.

Poster Session : Immunology ; Delivery of cellular proteins of T cell with Novel protein transduction domain Hph-1 inhibits T cell activation

( Kyun Do Kim ),( Jae Hun Shin ),( Jong Hyun Park ),( Sang Kyou Lee ) 한국생화학분자생물학회 (구 한국생화학회) 2007 생화학분자생물학회 춘계학술발표논문집 Vol.2007 No.-